quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:28:07·52d
SECFiling
Zymeworks Inc. logo

SEC Form 10-K filed by Zymeworks Inc.

ZYME· Zymeworks Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • ZYME
    Zymeworks Inc.
    Health Care

Recent analyst ratings

  • Dec 12UpdateWells Fargo$33.00
  • Dec 3UpdateCitizens JMP$32.00
  • Oct 24UpdateWells Fargo$15.00
  • Oct 14UpdateH.C. Wainwright$26.00
  • Oct 10UpdateB. Riley Securities$30.00
  • May 20UpdateTD Cowen-

Related

  • PR2d
    Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
  • PR6d
    Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
  • PR8d
    Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
  • SEC8d
    SEC Form SCHEDULE 13G filed by Zymeworks Inc.
  • INSIDER13d
    SEC Form 4 filed by Schayowitz Adam
  • INSIDER13d
    SEC Form 4 filed by Platshon Scott
  • INSIDER13d
    SEC Form 3 filed by new insider Platshon Scott
  • INSIDER13d
    SEC Form 3 filed by new insider Schayowitz Adam
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022